UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 8, 2016
COHERUS BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 001-36721 | | 27-3615821 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification Number) |
333 Twin Dolphin Drive, Suite 600
Redwood City, CA 94065
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code:(650) 649-3530
Check the appropriate box below if theForm 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant toRule 14a-12 under the Exchange Act(17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant toRule 14d-2(b) under the Exchange Act(17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant toRule 13e-4(c) under the Exchange Act(17 CFR 240.13e-4(c)) |
Item 2.02 Results of Operations and Financial Conditions
On August 9, 2016, Coherus BioSciences, Inc. (the “Company”) issued a press release regarding its financial results for its second quarter ended June 30, 2016. The full text of the press release is furnished as Exhibit 99.1 to thisForm 8-K.
This information in this Item 2.02 of thisForm 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 8.01 Other Events
On August 8, 2016, the Company issued a press release reporting that its ongoing Phase 3 study ofCHS-1420, its adalimumab (Humira®) biosimilar candidate, in patients with psoriasis, met its primary endpoint. The full text of this press release is furnished as Exhibit 99.2 to thisForm 8-K.
On August 9, 2016, the Company issued a press release reporting that it submitted a 351(k) biologics license application to the United States Food and Drug Administration forCHS-1701, its pegfilgrastim (Neulasta®) biosimilar candidate. The full text of this press release is furnished as Exhibit 99.3 to thisForm 8-K.
Item 9.01 Financial Statements and Exhibits.
| | |
Exhibit No. | | Description |
| |
| 99.1 | | Press release entitled “Coherus BioSciences Reports Second Quarter 2016 Financial and Operating Results” dated August 9, 2016 |
| |
| 99.2 | | Press release entitled “Coherus BioSciences Announces Positive Topline Phase Three Results forCHS-1420 (Humira® Biosimilar Candidate) in Patients with Psoriasis” dated August 8, 2016 |
| |
| 99.3 | | Press release entitled “Coherus BioSciences Submits 351(k) Biologics License Application to U.S. Food and Drug Administration forCHS-1701 (Pegfilgrastim Biosimilar Candidate)” dated August 9, 2016 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| Date: August 9, 2016 | | | | COHERUS BIOSCIENCES, INC. |
| | | |
| | | | By: | | /s/ Jean-Frédéric Viret |
| | | | Name: | | Jean-Frédéric Viret |
| | | | Title: | | Chief Financial Officer |
EXHIBIT INDEX
| | |
Exhibit No. | | Description |
| |
| 99.1 | | Press release entitled “Coherus BioSciences Reports Second Quarter 2016 Financial and Operating Results” dated August 9, 2016 |
| |
| 99.2 | | Press release entitled “Coherus BioSciences Announces Positive Topline Phase Three Results forCHS-1420 (Humira® Biosimilar Candidate) in Patients with Psoriasis” dated August 8, 2016 |
| |
| 99.3 | | Press release entitled “Coherus BioSciences Submits 351(k) Biologics License Application to U.S. Food and Drug Administration forCHS-1701 (Pegfilgrastim Biosimilar Candidate)” dated August 9, 2016 |
